Shanghai Pharmaceuticals Holding (601607.SH): The listing application for Lacosamide API has been approved.
Connecting global capital markets
Announcement: Shanghai Pharmaceuticals Holding (601607.SH) announced that its wholly-owned subsidiary Shangyao Kangli (Changzhou) Pharmaceuticals Co., Ltd. ("Shangyao Kangli") has received the "Chemical Raw Material Drug Market Application Approval Notice" (Notice No.: 2023YS00679) issued by the State Drug Administration ("National Drug Administration") for its drug Lakaosha'an. The drug has been approved for production.
Related Articles
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
Cui Dongshu: By 2025, the total national second-hand car transaction volume will be 20.11 million units, an increase of 2.5% year-on-year.
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
Cui Dongshu: By 2025, the total national second-hand car transaction volume will be 20.11 million units, an increase of 2.5% year-on-year.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
